-
Mashup Score: 8BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update - 3 year(s) ago
Treatment for hepatocellular carcinoma (HCC) has experienced major advancements since the last update of the official Barcelona Clinic Liver Cancer (BCLC) prognosis and treatment strategy published in 2018. Advancements in the field have emerged in all areas, but in this manuscript, we present those that have primed a change in the strategy and comment why some encouraging data in select…
Source: Journal of HepatologyCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 1Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score - 3 year(s) ago
Immunotherapy with atezolizumab plus bevacizumab represents the new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC). Prognostic biomarkers are an unmet need.
Source: Journal of HepatologyCategories: Hematologists1, Latest HeadlinesTweet-
CRAFITY (CRP and AFP in ImmunoTherapY) score predicts outcome in liver cancer patients receiving immunotherapy https://t.co/5lYBwLhCzL https://t.co/t67kNTAnw6
-
-
Mashup Score: 0Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma - 3 year(s) ago
Intratumor molecular heterogeneity is a key feature of tumorigenesis and is linked to treatment failure and patient prognosis. Herein, we aimed to determine what drives tumor cell evolution by performing single-cell transcriptomic analysis.
Source: Journal of HepatologyCategories: Gastroenterology, Latest HeadlinesTweet-
#YearinReview Top pick - Single-cell transcriptomic profiling of primary liver tumours (HCC & intrahepatic CCA) identified intratumoural cell states & degree of diversity in @JHepatology https://t.co/3cgtFBb7S0
-
-
Mashup Score: 1Sarcopenia and frailty in decompensated cirrhosis - 3 year(s) ago
In patients with decompensated cirrhosis, sarcopenia and frailty are prevalent. Although several definitions exist for these terms, in the field of hepatology, sarcopenia has commonly been defined as loss of muscle mass, and frailty has been broadly defined as the phenotypic manifestation of the loss of muscle function. Prompt recognition and accurate assessment of these conditions are critical…
Source: Journal of HepatologyCategories: Gastroenterology, Latest HeadlinesTweet-
A must read 📰 by Tandon et al in @JHepatology - '#Sarcopenia & #frailty in decompensated #cirrhosis' https://t.co/OBgx32MJty #livertwitter #GITwitter https://t.co/T21UKmS7UH
-
-
Mashup Score: 0A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers - 3 year(s) ago
Only a minority of excess alcohol drinkers develop cirrhosis. We developed and evaluated risk stratification scores to identify those at highest risk.
Source: Journal of HepatologyCategories: Hematologists1, Latest HeadlinesTweet-
Genetic risk score (GRS- 3 SNPs -PNPLA3:rs738409, SUGP1-TM6SF2:rs10401969, HSD17B13:rs6834314and diabetes ) can identify patients at high risk of developing alcohol-related cirrhosis of the liver https://t.co/bhDfRKqIT4 https://t.co/kI5RzwyWiP
-
-
Mashup Score: 3
In many countries worldwide, the burden of hepatocellular carcinoma (HCC) associated with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) is increasing. Preventive strategies are needed to counteract this trend. In this review, we provide an overview of the evidence on preventive strategies in NAFLD-associated HCC. We consider the impact of lifestyle factors…
Source: Journal of HepatologyCategories: Latest Headlines, Oncologists2Tweet-
RT @ELSgastro: Read "Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention" #OpenAccess here https://t.co/3Itd5RETJi…
-
-
Mashup Score: 6TAZ is indispensable for c-MYC-induced hepatocarcinogenesis - 3 year(s) ago
Mounting evidence implicates the Hippo downstream effectors Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) in hepatocellular carcinoma (HCC). We investigated the functional contribution of YAP and/or TAZ during c-MYC induced liver tumor development.
Source: Journal of HepatologyCategories: Gastroenterology, Latest HeadlinesTweet-
#GastroEdPick A new study identifies TAZ as a transcriptional target of c-MYC during hepatocarcinogenesis, and activated TAZ/YAP regulate an anti-apoptotic gene (BCL2L12) to promote c-MYC-induced tumour development. #HCC @JHepatology https://t.co/MJPxAE2Zaz
-
-
Mashup Score: 4Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors - 3 year(s) ago
Portal vein thrombosis (PVT) is a relatively frequent event in patients with cirrhosis. Different risk factors for PVT have been reported, such as decreased portal flow velocity (PBFV) and parameters related with severity of portal hypertension. However, most of these studies are retrospective and only a discrete number of parameters potentially implicated in PVT development were evaluated.The…
Source: Journal of HepatologyCategories: Hem/Oncs, Latest HeadlinesTweet-
369 cirrhotic patient prospective study. 29 cases of portal vein thrombosis (PVT) during follow-up. Risk factors for PVT were those of portal hypertension and NOT inherited of acquired thrombophilia. https://t.co/8By5nnls9t https://t.co/pGcKF1vSfQ
-
-
Mashup Score: 13Granulocyte-Colony Stimulating Factor (G-CSF) to treat acute-on-chronic liver failure, a multicenter randomized trial (GRAFT study) - 3 year(s) ago
Acute-on-chronic liver failure (ACLF) is a syndrome that develops in patients with decompensated liver cirrhosis and which is characterized by organ failure and poor short-term prognosis. Based on positive results from small single center studies, Granulocyte-Colony Stimulating Factor (G-CSF) is being widely used in the treatment of ACLF patients. The aim of that study was to evaluate the safety…
Source: Journal of HepatologyCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @ebtapper: G-CSF does not help acute-on-chronic liver failure A terrific multicenter RCT in @JHepatology https://t.co/ajT4BsyiqI 186…
-
-
Mashup Score: 1
Maternal obesity has been linked to the development of cardiovascular disease and diabetes in offspring, but its relationship to non-alcoholic fatty liver disease (NAFLD) is unclear.
Source: Journal of HepatologyCategories: Healthcare Professionals, Latest HeadlinesTweet-
Maternal obesity increases the risk and severity of NAFLD in offspring - Journal of Hepatology https://t.co/SiFhNGosMF
-
Barcelona Clinic Liver Cancer staging system- 2022 update https://t.co/KGkAa2z0Q9 https://t.co/70al8cZmDc